1ypq: Difference between revisions

No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:


==Human Oxidized Low Density Lipoprotein Receptor LOX-1 Dioxane Complex==
==Human Oxidized Low Density Lipoprotein Receptor LOX-1 Dioxane Complex==
<StructureSection load='1ypq' size='340' side='right' caption='[[1ypq]], [[Resolution|resolution]] 1.40&Aring;' scene=''>
<StructureSection load='1ypq' size='340' side='right'caption='[[1ypq]], [[Resolution|resolution]] 1.40&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[1ypq]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YPQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1YPQ FirstGlance]. <br>
<table><tr><td colspan='2'>[[1ypq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YPQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1YPQ FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DIO:1,4-DIETHYLENE+DIOXIDE'>DIO</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.4&#8491;</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1ypu|1ypu]], [[1ypo|1ypo]]</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DIO:1,4-DIETHYLENE+DIOXIDE'>DIO</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1ypq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1ypq OCA], [http://pdbe.org/1ypq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1ypq RCSB], [http://www.ebi.ac.uk/pdbsum/1ypq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=1ypq ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1ypq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1ypq OCA], [https://pdbe.org/1ypq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1ypq RCSB], [https://www.ebi.ac.uk/pdbsum/1ypq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1ypq ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
[[http://www.uniprot.org/uniprot/OLR1_HUMAN OLR1_HUMAN]] Note=Independent association genetic studies have implicated OLR1 gene variants in myocardial infarction susceptibility.<ref>PMID:12384789</ref> <ref>PMID:12807963</ref> <ref>PMID:15060104</ref> <ref>PMID:15276231</ref> <ref>PMID:15860461</ref>  Note=OLR1 may be involved in Alzheimer disease (AD). Involvement in AD is however unclear: according to some authors (PubMed:12354387, PubMed:12810610 and PubMed:15976314), variations in OLR1 modify the risk of AD, while according to other (PubMed:15000751 and PubMed:15060104) they do not.<ref>PMID:12384789</ref> <ref>PMID:12807963</ref> <ref>PMID:15060104</ref> <ref>PMID:15276231</ref> <ref>PMID:15860461</ref>
[https://www.uniprot.org/uniprot/OLR1_HUMAN OLR1_HUMAN] Note=Independent association genetic studies have implicated OLR1 gene variants in myocardial infarction susceptibility.<ref>PMID:12384789</ref> <ref>PMID:12807963</ref> <ref>PMID:15060104</ref> <ref>PMID:15276231</ref> <ref>PMID:15860461</ref>  Note=OLR1 may be involved in Alzheimer disease (AD). Involvement in AD is however unclear: according to some authors (PubMed:12354387, PubMed:12810610 and PubMed:15976314), variations in OLR1 modify the risk of AD, while according to other (PubMed:15000751 and PubMed:15060104) they do not.<ref>PMID:12384789</ref> <ref>PMID:12807963</ref> <ref>PMID:15060104</ref> <ref>PMID:15276231</ref> <ref>PMID:15860461</ref>  
== Function ==
== Function ==
[[http://www.uniprot.org/uniprot/OLR1_HUMAN OLR1_HUMAN]] Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.<ref>PMID:9052782</ref> <ref>PMID:11821063</ref> <ref>PMID:12354387</ref>
[https://www.uniprot.org/uniprot/OLR1_HUMAN OLR1_HUMAN] Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.<ref>PMID:9052782</ref> <ref>PMID:11821063</ref> <ref>PMID:12354387</ref>  
== Evolutionary Conservation ==
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
[[Image:Consurf_key_small.gif|200px|right]]
Line 17: Line 17:
   <jmolCheckbox>
   <jmolCheckbox>
     <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/yp/1ypq_consurf.spt"</scriptWhenChecked>
     <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/yp/1ypq_consurf.spt"</scriptWhenChecked>
     <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
     <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked>
     <text>to colour the structure by Evolutionary Conservation</text>
     <text>to colour the structure by Evolutionary Conservation</text>
   </jmolCheckbox>
   </jmolCheckbox>
Line 31: Line 31:
</div>
</div>
<div class="pdbe-citations 1ypq" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 1ypq" style="background-color:#fffaf0;"></div>
==See Also==
*[[LDL receptor|LDL receptor]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Human]]
[[Category: Homo sapiens]]
[[Category: Adsit, F G]]
[[Category: Large Structures]]
[[Category: Boyington, J C]]
[[Category: Adsit FG]]
[[Category: Park, H]]
[[Category: Boyington JC]]
[[Category: C-type lectin like domain]]
[[Category: Park H]]
[[Category: Ctld]]
[[Category: Immune system]]
[[Category: Lox-1]]
[[Category: Nk cell receptor]]
[[Category: Oxidized low density lipoprotein receptor]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA